SCHEMBL4284784

SCHEMBL4284784

Cc1ccc(Nc2nccc(Oc3ccc4[nH]ccc4c3)n2)cc1F

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SYK P43405 6/20 0.50
KDR P35968 6/20 0.42
FGFR1 P11362 1/20 0.42
FLT1 P17948 1/20 0.42
FLT4 P35916 1/20 0.42
FLT3 P36888 1/20 0.42
MERTK Q12866 1/20 0.42
NTRK2 Q16620 1/20 0.42
EGFR P00533 3/20 0.42
AURKA O14965 1/20 0.41
MAP4K4 O95819 1/20 0.41
PIM1 P11309 1/20 0.41
CDK2 P24941 1/20 0.41
MAPK8 P45983 1/20 0.41
GSK3B P49841 1/20 0.41
AURKB Q96GD4 1/20 0.41
HIPK2 Q9H2X6 1/20 0.41
CLK4 Q9HAZ1 1/20 0.41
MKNK2 Q9HBH9 1/20 0.41
IRAK4 Q9NWZ3 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4287633 0.91 SYK (0.50) SYKKDRFGFR1FLT1FLT4
SCHEMBL13805488 0.88 SYK (0.50) SYKKDRFGFR1FLT1FLT4
SCHEMBL4279518 0.86 SYK (0.48) SYKKDRFGFR1FLT1FLT4
SCHEMBL4287649 0.84 SYK (0.47) SYKKDRFGFR1FLT1FLT4
SCHEMBL4279207 0.83 ABL1 (0.45) SYKKDREGFRJAK2
SCHEMBL4283784 0.83 KDR (0.49) SYKKDRFGFR1FLT1FLT4
SCHEMBL4287689 0.83 KDR (0.50) SYKKDRFGFR1FLT1FLT4
SCHEMBL4287622 0.82 SYK (0.48) SYKKDRFGFR1FLT1FLT4
SCHEMBL4281016 0.82 KDR (0.54) SYKKDRFGFR1FLT1FLT4
SCHEMBL13805489 0.80 ABL1 (0.44) SYKKDRFGFR1FLT1FLT4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090149467-A1 Tyrosine Kinase Inhibitors MERCK & CO., INC. (US) 2009-06-11 US claimed
EP-1934200-A1 TYROSINE KINASE INHIBITORS Merck & Co., Inc. (US) 2008-06-25 EP claimed
WO-2007035309-A1 TYROSINE KINASE INHIBITORS MERCK & CO., INC. (US) 2007-03-29 WO claimed
US-20090149467-A1 Tyrosine Kinase Inhibitors MERCK & CO., INC. (US) 2009-06-11 US disclosed
US-20090149467-A1 Tyrosine Kinase Inhibitors MERCK & CO., INC. (US) 2009-06-11 US disclosed
US-20090149467-A1 Tyrosine Kinase Inhibitors MERCK & CO., INC. (US) 2009-06-11 US disclosed
EP-1934200-A1 TYROSINE KINASE INHIBITORS Merck & Co., Inc. (US) 2008-06-25 EP disclosed
WO-2007035309-A1 TYROSINE KINASE INHIBITORS MERCK & CO., INC. (US) 2007-03-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090149467-A1 Tyrosine Kinase Inhibitors ABL1, MET, ERBB2 SYK 86/4885KDR 165/4885FGFR1 68/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.